Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ciclosporin 1mg/ml eye drops 0.3ml unit dose
1104020AEAAAAAA
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | 13,382 |
|
Ciclosporin 0.2% eye ointment
1104020AEAAAGAG
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | 17 |
|
Ciclosporin 0.2% eye ointment preservative free
1104020AEAAAFAF
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | 11 |
|
Ciclosporin 900microg/ml eye drops 0.25ml ud preserv free
1104020AEAAABAB
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | 11 |
|
Ciclosporin 0.05% eye dps 0.4ml unit dose preservative free
1104020AEAAAJAJ
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | 6 |
|
Ciclosporin 0.06% eye dps 0.4ml unit dose preservative free
1104020AEAAAIAI
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | No data available |
|
Ciclosporin 0.06% eye drops preservative free
1104020AEAAAHAH
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | No data available |
|
Ciclosporin 2% eye drops
1104020AEAAAEAE
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | No data available |
|
Ciclosporin 2% eye drops preservative free
1104020AEAAADAD
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | No data available |
|
Ciclosporin 2% eye ointment
1104020AEAAACAC
|
Ciclosporin (Eye Anti Inflammatory) | Ciclosporin (Eye Anti Inflammatory) | Eye | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.